Homeopathy for Chronic Non-specific Low Back Pain: Study Protocol for a Randomized, Double-Blind, Crossover, Placebo-Controlled Clinical Trial Investigating the Efficacy of the Biotherapic Lumbar Vertebra (The BIOVERT Trial)

Abstract

Background Chronic non-specific low back pain (CNSLBP) lacks identifiable anatomical pathology and effective pharmacological treatment. Alternative approaches in homeopathy, specifically clinical homeopathy, utilize ultra-diluted (potentized) biological products. In Brazil, standardized biotherapics from sheep tissues, particularly fifty-millesimal (LM) potencies of sheep Lumbar Vertebra, have shown promise in alleviating CNSLBP.

Objectives Our objective is to present the study protocol of a clinical trial that will assess the efficacy and safety of the biotherapic Lumbar Vertebra LM2 in the short-term management of CNSLBP and to estimate its therapeutic duration.

Methods A randomized, double-blind, crossover, placebo-controlled clinical trial spanning 8 weeks per participant was designed. Participants will include 120 individuals (aged 20 to 60 years) with clinically diagnosed CNSLBP by the study's physiotherapist. Exclusion criteria are radicular pain, signs of radiculopathy, specific lumbar spine disorders, pregnancy, or puerperium (up to 60 days after delivery). The medical intervention includes participants being randomly assigned to one of two treatment sequences: homeopathy–placebo or placebo–homeopathy. The treatments will consist of Lumbar Vertebra LM2 oral solution, topical cream, and indistinguishable placebos. Each treatment period will span 2 weeks, with a 4-week washout interval between them. Primary outcome is the assessment of changes in self-reported pain levels using the numeric rating scale (NRS) score, analyzed with a random effects model across both treatment periods. Secondary outcomes are assessment of changes in self-reported disability levels using the Oswestry Disability Index (ODI), analyzed with a random effects model across both treatment periods, and pain and disability variations, evaluated by the NRS score and ODI respectively, after the first and second treatment periods. Adverse events will be assessed at weeks 2 and 8. Pain medications will be used concomitantly. Adherence will be evaluated by the weight of medication returned/standard weight.

Discussion The BIOVERT (Bioactive Vertebra) trial protocol is designed to investigate a homeopathic strategy for short-term CNSLBP treatment. Favorable outcomes for homeopathy could prompt subsequent studies evaluating the long-term effectiveness of LM potencies of Lumbar Vertebra for CNSLBP.

Trial Registration UMIN Clinical Trials Registry – ID: UMIN000051957

Keywords

homeopathy - biotherapics - low back pain - clinical study

Publication History

Received: 28 August 2023

Accepted: 03 October 2023

Article published online:
20 March 2024

• References

• 1 Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet 2017; 389 (10070): 736-747
• 2 de David CN, Deligne LMC, da Silva RS. et al. The burden of low back pain in Brazil: estimates from the Global Burden of Disease 2017 Study. Popul Health Metr 2020; 18: 12
• 3 Price MR, Cupler ZA, Hawk C, Bednarz EM, Walters SA, Daniels CJ. Systematic review of guideline-recommended medications prescribed for treatment of low back pain. Chiropr Man Therap 2022; 30: 26
• 4 Enthoven WT, Roelofs PD, Deyo RA, van Tulder MW, Koes BW. Non-steroidal anti-inflammatory drugs for chronic low back pain. Cochrane Database Syst Rev 2016; 2: CD012087
• 5 Hägg O, Fritzell P, Nordwall A. Swedish Lumbar Spine Study Group. The clinical importance of changes in outcome scores after treatment for chronic low back pain. Eur Spine J 2003; 12: 12-20
• 6 Bindu S, Mazumder S, Bandyopadhyay U. Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective. Biochem Pharmacol 2020; 180: 114147
• 7 Furlan AD, van Tulder MW, Cherkin DC. et al. Acupuncture and dry-needling for low back pain. Cochrane Database Syst Rev: CD001351
• 8 Gmünder R, Kissling R. Die Wirkung von klassischer Homöopathie im Vergleich mit standardisierter Physiotherapie bei der Behandlung von chronischen Kreuzschmerzen [The efficacy of homeopathy in the treatment of chronic low back pain compared to standardized physiotherapy]. z Orthop Ihre Grenzgeb 2002; 140: 503-508
• 9 Stam C, Bonnet MS, van Haselen RA. The efficacy and safety of a homeopathic gel in the treatment of acute low back pain: a multi-centre, randomised, double-blind comparative clinical trial. Br Homeopath J 2001; 90: 21-28
• 10 Beer AM, Fey S, Zimmer M, Teske W, Schremmer D, Wiebelitz KR. Wirksamkeit und Sicherheit eines homöopathischen Komplexpräparates bei chronischen Rückschmerzen. Doppelblinde, randomisierte, placebokontrollierte, klinische Studie [Effectiveness and safety of a homeopathic drug combination in the treatment of chronic low back pain. A double-blind, randomized, placebo-controlled clinical trial]. MMW Fortschr Med 2012; 154: 48-57
• 11 Schmidt JM. Samuel Hahnemann und das Ahnlichkeitsprinzip [Samuel Hahnemann and the principle of similars]. Medizin, Gesellschaft, und Geschichte. Jahrb Inst Gesch Med Robert Bosch Stift 2010; 29: 151-184
• 12 Brasil, Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Atenção Básica. Política Nacional de Práticas Integrativas e Complementares no SUS. 2ª ed. – Brasília: Ministério da Saúde, 2015. Accessed August 27, 2023. Available at: https://bvsms.saude.gov.br/bvs/publicacoes/politica_nacional_praticas_integrativas_complementares_2ed.pdf
• 13 Hahnemann S. Organon der Heilkunst: aude sapere. 6th ed.. Editor: Richard Haehl.; Heidelberg; Haug; 1988: 270
• 14 Brasil, Ministério da Saúde. Agência Nacional de Vigilância Sanitária. Farmacopeia Homeopática Brasileira: 3ª edição, 2011. Accessed August 27, 2023. Available at: https://www.gov.br/anvisa/pt-br/assuntos/farmacopeia/farmacopeia-homeopatica/arquivos/8048json-file-1
• 15 Perella C. . Constantine Hering: The Father of American Homeopathy. Accessed August 27, 2023 at: https://drexel.edu/legacy-center/blog/overview/2013/december/constantine-hering-the-father-of-american-homeopathy/
• 16 Bellavite P, Conforti A, Piasere V, Ortolani R. Immunology and homeopathy. 1. Historical background. Evid Based Complement Alternat Med 2005; 2: 441-452
• 17 Van Wassenhoven M, Ives G. An observational study of patients receiving homeopathic treatment. Homeopathy 2004; 93: 3-11
• 18 Horta I. Estudo prospectivo observacional de uma série de casos de dor osteomusculoarticular crônica com organoterápicos associados ao tratamento homeopático convencional / Prospective observational study of a case-series of chronic bone, muscle and joint pain with organotherapy associated with conventional homeopathic treatment. Rev Homeopatia (Säo Paulo) 2012; 75: 1-13
• 19 Grelle LCE, Camacho LAB. Homeopathic treatment of subclinical hypothyroidism—a series of 19 cases. Homeopathy 2022; 111: 184-193
• 20 Cesar AT, Sollero PA, Cegalla VT. Mangieri Jr R. Organoterápicos a partir de tecidos de carneiro: relato etnográfico e preparação/Organotherapy medicines from sheep: ethnographic report and preparation. Rev Homeopatia (São Paulo) 2016; 79: 49-58
• 21 Sedgwick P. What is a crossover trial?. BMJ 2014; 348: g3191
• 22 Chan A-W, Tetzlaff JM, Altman DG. et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013; 158: 200-207
• 23 Brasil, Ministério da Saúde. Conselho Nacional da Saúde. Diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos. Resolução n° 466 de 12/12/2012. Accessed August 27, 2023. Available at: https://www.gov.br/ebserh/pt-br/ensino-e-pesquisa/pesquisa-clinica/resolucao-466.pdf
• 24 Brasil, Lei Geral de Proteção de Dados - n° 13.709, de 14 de agosto de 2018. Accessed August 27, 2023. Available at: https://www.planalto.gov.br/ccivil_03/_ato2015-2018/2018/lei/l13709.htm
• 25 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Integrated Addendum to ICH E6(R1): Guideline For Good Clinical Practice E6(R2). Accessed August 27, 2023. Available at: https://database.ich.org/sites/default/files/E6_R2_Addendum.pdf
• 26 Dean ME, Coulter MK, Fisher P, Jobst KA, Walach H. Reporting data on homeopathic treatments (RedHot): a supplement to CONSORT. J Altern Complement Med 2007; 13: 19-23
• 27 Costa LO, Maher CG, Latimer J. et al. Clinimetric testing of three self-report outcome measures for low back pain patients in Brazil: which one is the best?. Spine 2008; 33: 2459-2463
• 28 Vigatto R, Alexandre NM, Correa Filho HR. Development of a Brazilian Portuguese version of the Oswestry Disability Index: cross-cultural adaptation, reliability, and validity. Spine 2007; 32: 481-486
• 29 Falavigna A, Teles AR, Braga GL, Barazzetti DO, Lazzaretti L, Tregnago AC. Instrumentos de avaliação clínica e funcional em cirurgia da coluna vertebral. Coluna/Columna 2011; 10: 62-67
• 30 Vibe Fersum K, O'Sullivan P, Skouen JS, Smith A, Kvåle A. Efficacy of classification-based cognitive functional therapy in patients with non-specific chronic low back pain: a randomized controlled trial. Eur J Pain 2013; 17: 916-928
• 31 Malik KM, Nelson AM, Chiang TH, Imani F, Khademi SH. The specifics of non-specific low back pain: re-evaluating the current paradigm to improve patient outcomes. Anesth Pain Med 2022; 12: e131499
• 32 Schoenfeld D. . Statistical considerations for a cross-over study where the outcome is a measurement. Accessed August 27, 2023. Available at: http://hedwig.mgh.harvard.edu/sample_size/js/js_crossover_quant.html
• 33 Sealed Envelope Ltd. 2022. Create a blocked randomisation list. Accessed August 27, 2023. Available at: https://www.sealedenvelope.com/simple-randomiser/v1/lists
• 34 Sorteio.com. Accessed August 27, 2023. Available at: https://sorteio.com/sorteio-de-nomes
• 35 Lim CY, In J. Considerations for crossover design in clinical study. Korean J Anesthesiol 2021; 74: 293-299
• 36 Lui KJ, Chang KC. Analysis of Poisson frequency data under a simple crossover trial. Stat Methods Med Res 2016; 25: 385-399
• 37 Ezzet F, Whitehead J. A random effects model for ordinal responses from a crossover trial. Stat Med 1991; 10: 901-906 , discussion 906–907
• 38 Myers WR. Handling missing data in clinical trials: an overview. Drug Inf J 2000; 34: 525-533
• 39 Allen EN, Chandler CI, Mandimika N, Leisegang C, Barnes K. Eliciting adverse effects data from participants in clinical trials. Cochrane Database Syst Rev 2018; 1: MR000039